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Strengths and limitations of this study
 ► As a multinational trial, this study will provide in-
ternationally generalisable results concerning the 
effects of music interventions delivered by trained 
informal caregivers on the behavioural and psycho-
logical symptoms of people living with dementia.
 ► Based on pilot data, this trial will have adequate 
power to determine any effects on the person with 
dementia.
 ► The trial will determine whether caregiver- delivered 
music interventions improve caregiver quality of life 
and well- being, and reduce healthcare costs for the 
caregiver and society.
 ► A comprehensive set of core outcomes will be mea-
sured, including long- term effects in key variables, 
with assessor blinding.
 ► As participants cannot be blinded, a limitation of the 
study is that they may provide biased responses on 
self- report measures.
AbStrACt
Introduction Pharmacological interventions to address 
behavioural and psychological symptoms of dementia 
(BPSD) can have undesirable side effects, therefore non- 
pharmacological approaches to managing symptoms may 
be preferable. Past studies show that music therapy can 
reduce BPSD, and other studies have explored how formal 
caregivers use music in their caring roles. However, no 
randomised study has examined the effects on BPSD of 
music interventions delivered by informal caregivers (CGs) 
in the home setting. Our project aims to address the need 
for improved informal care by training cohabiting family 
CGs to implement music interventions that target BPSD, 
and the quality of life (QoL) and well- being of people with 
dementia (PwD) and CGs.
Methods and analysis A large international three- arm 
parallel- group randomised controlled trial will recruit a 
sample of 495 dyads from Australia, Germany, UK, Poland 
and Norway. Dyads will be randomised equally to standard 
care (SC), a home- based music programme plus SC, or a 
home- based reading programme plus SC for 12 weeks. 
The primary outcome is BPSD of PwD (measured using 
the Neuropsychiatric Inventory- Questionnaire). Secondary 
outcomes will examine relationship quality between CG 
and PwD, depression, resilience, competence, QoL for CG 
and QoL for PwD. Outcomes will be collected at baseline, 
at the end of the 12- week intervention and at 6 months 
post randomisation. Resource Utilisation in Dementia will 
be used to collect economic data across the life of the 
intervention and at 6- month follow- up. We hypothesise 
that the music programme plus SC will generate better 
results than SC alone (primary comparison) and the 
reading programme plus SC (secondary comparison).
Ethics and dissemination Ethical approval has been 
obtained for all countries. Results will be presented at 
national and international conferences and published in 
scientific journals and disseminated to consumer and 
caregiver representatives and the community.
trial registration numbers ACTRN12618001799246p; 
NCT03907748
bACkground
Family caregivers (CG) play a vital role 
in providing care for a person living with 
dementia (PwD) in the home setting.1 This 
personalised care directly benefits the PwD by 
keeping them at home in a familiar environ-
ment and represents a significant economic 
contribution to society. CGs often find care-
giving satisfying and rewarding, however the 
task of managing the challenging behavioural 
and psychological symptoms of dementia 
(BPSD) can override their capacity to cope, 
leading to negative physical and mental 
health including fatigue, depression, burnout 
and illness.2 3 A deterioration in CG well- 
being may have a negative flow- on effect on 
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Figure 1 Mechanisms of action underpinning the music intervention. BPSD, behavioural and psychological symptoms of 
dementia; CG, caregiver; MI, music intervention; PwD, people with dementia; QoL, quality of life.
the well- being of the PwD. A negative spiral may develop 
until the CG can no longer sustain the caring role, and 
the PwD moves into residential care earlier than desired.
The 2015 global cost of dementia was estimated to be 
US$818 billion, and this figure will continue to increase 
as the number of people with dementia rises.1 Nearly 85% 
of costs are related to family and social care, rather than 
medical care. With this increase and the escalating costs 
of care, it is time- critical that CG- directed home- based 
interventions are developed and tested. The 2017 Lancet 
Commission on Dementia1 suggests that pharmacological 
treatment of BPSD should be restricted to those with very 
severe symptoms and highlights music therapy as a non- 
pharmacological intervention that reduces BPSD (p.30).
Systematic reviews indicate that the majority of CG- di-
rected interventions adopted cognitive- behavioural 
or psychoeducational approaches to address CG 
coping, depression and BPSD management.4 5 Adher-
ence to programmes was poor because CGs could not 
commit to the regular programme attendance require-
ments.4 5 Drawing on social exchange theory, apathy and 
other BPSD lead to diminished reciprocity between CG 
and PwD, creating imbalances in the relationship.6 There-
fore, the convenience of a home- based CG- delivered 
programme that can manage BPSD and address relation-
ship reciprocity is more likely to be adhered to, and more 
effective in promoting both PwD and CG well- being.
Music therapy is a registered psychosocial National 
Health Service (NHS in the UK) intervention that 
meets the current recommendations for addressing the 
individual needs of those with dementia.7 HOMESIDE 
(HOME- based caregiver- delivered music intervention 
for people living with dementia) uses a purposefully 
developed music intervention (MI) (described later) 
informed by previous meta- analyses that demonstrate the 
effectiveness of music therapy in reducing BPSD.8–11 The 
MI is a translation of the research evidence to a home- 
care context and, instead of being delivered directly by 
qualified music therapists, they will train CGs to deliver 
the MI. The MI incorporates Kitwood’s model of person-
hood for PwD,12 which is essential to effective dementia 
care and underpins the philosophy of the 2018 Alzhei-
mer’s Association Dementia Care Practice Recommen-
dations. The person- centred dementia care embedded 
in the MI emphasises communication and relationships, 
recognising that dementia is best understood as an inter-
play between neurological impairment and psychoso-
cial factors (eg, health, individual psychology) and the 
environment.13
Small- scale studies that have tested the effectiveness 
of MI training programme for informal and formal CGs 
have had positive findings to date. Results of a cluster 
randomised controlled trial (RCT) with formal CGs 
showed the MI to be a practicable and acceptable inter-
vention, with PwD showing treatment- related improve-
ments, and staff reporting enhanced skills in caregiving.8 
Although based on a small sample (n=17), large effects 
in BPSD (Cohen’s d=2.32) were found between standard 
care (SC) and MI from baseline to 7 months. A home- 
based feasibility RCT determined acceptability of the MI, 
assessed burden associated with delivering the MI and 
tested appropriateness of the measures.14 BPSD scores 
decreased from baseline to post- test in the MI group but 
increased in the SC group and mixed results were shown 
for the comparative reading group. A study involving eight 
family CGs who were trained to deliver home- based music 
programmes for their care recipient with dementia found 
that both CGs and PwD improved in self- reported relax-
ation, comfort and happiness from baseline to post- test. 
Music activities taught to CGs comprised music listening 
with reminiscence, movement to music, music and 
progressive muscle relaxation, drawing and discussing 
drawing to music, singing, percussion instrument playing 
and strategic use of music for use while performing activ-
ities of daily living. CGs seemed to derive great benefit 
from the programme in comparison with care recipients. 
Findings suggested that CGs enjoyed partaking in the 
reminiscing and shared musical activities with their loved 
ones.15
The conceptual framework underpinning the MI incor-
porates the responses of the PwD, the ensuing moment- 
to- moment interaction between the PwD and the CG and 
the CGs’ responses to the PwD and moments of interac-
tion (figure 1). The MI is grounded in the established 
knowledge that music- induced emotions and memories 
are often retained in PwD because of the relative preser-
vation of medial frontal and limbic areas.9 16 MIs are effec-
tive when the music selected for use is chosen by the PwD 
(or CG).9 11 When music facilitates moment- to- moment 
interactions, emotional and social engagement and auto-
biographical recall, imbalances in reciprocity are dimin-
ished. CGs’ positive experience of seeing ‘the person 
behind the dementia’ via this music- induced response 
evokes CG experiences of pleasure, feelings of compe-
tence in the CG and fosters their resilience and coping. 
Ultimately, the enhanced well- being of CGs will lead to 
more effective care and better well- being outcomes for 
both CGs and PwD (figure 1).
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Figure 2 HOMESIDE illustration of study design.
The comparative conditions in this trial are SC only 
(control) and a reading intervention plus SC (RI, active 
control). The RI was included because studies have 
shown preliminary evidence that reading to and with PwD 
can have positive impacts on BPSD.17 18 We anticipate the 
MI to be superior to SC only. In addition, we postulate 
that the RI will lead to a small positive effect but the MI 
is expected to be superior as music has been shown to 
be a social connector and a trigger of autobiographical 
recall, is non- reliant on intact verbal comprehension or 
expression and can be used to regulate emotion and 
behaviour.7 9–11 16 19–22
trial design
A large, pragmatic, single- blinded, international three- arm 
parallel- group RCT design is planned with a 1:1:1 alloca-
tion ratio. Cohabiting dyads where one member of each 
dyad has a diagnosis of dementia will be randomised to 
one of three conditions: 1) MI plus SC; 2) RI plus SC 
and 3) SC only (figure 2). CGs in MI and RI groups will 
receive a 2- hour training session on how to deliver the MI 
or RI and will then engage the PwD in a 5x weekly CG- di-
rected home- programme for 12 weeks. Two additional 
training sessions will be provided at 3 and 6 weeks post 
allocation. Fifteen- minute fortnightly phone calls will 
be scheduled to support the CG, and encourage adher-
ence to the protocol. Data will be collected at baseline, 
at the end of the 12- week intervention and at 3- month 
follow- up (6 months postrandomisation). The SC group 
will not receive any training sessions. This trial is framed 
as a superiority trial where we hypothesise that the MI will 
be superior to SC (primary) and RI plus SC (secondary) 
regarding BPSD of PwD at 12 weeks postrandomisation.
objectives
The aim is to demonstrate the effectiveness of the 
12- week HOMESIDE MI plus SC on the short- term BPSD 
at the end of intervention of PwD living at home and 
being cared for by a cohabiting CG compared with SC 
(primary), and to evaluate the effectiveness of MI plus SC 
compared with RI plus SC (secondary). Other secondary 
objectives are as follows:
 ► Evaluate the maintenance of the effect of the MI plus 
SC on long- term (6 months postrandomisation) BPSD 
compared with SC and RI plus SC.
 ► Evaluate the effectiveness of the MI plus SC on short- 
term and long- term levels of depression and QoL of 
PwD compared with SC and RI plus SC.
 ► Evaluate the effectiveness of the MI plus SC on short- 
term and long- term levels of depression, resilience, 
sense of competence and QoL of the CG compared 
with SC and RI plus SC.
 ► Evaluate the effectiveness of the MI plus SC on the 
short- term and long- term perceived quality of the 
relationship between PwD and CG compared with SC 
and RI plus SC.
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 ► Compare the cost- effectiveness of a CG- delivered MI 
plus SC on PwD and CG outcomes compared with 
SC and RI plus SC, using health- related QoL for both 
PwD and CG.
MEthodS And AnAlySIS
Participants
The trial will be conducted in people’s homes located in 
metropolitan cities and adjoining rural areas in Australia, 
Germany, Poland, Norway and the UK.
Inclusion criteria:
 ► Dyads (cohabiting) who are close in relationship 
and where one member has a diagnosis of dementia 
according to the 10th revision of the International 
Statistical Classification of Diseases and Related 
Health Problems (ICD-10) criteria (Alzheimer’s 
disease (AD), frontotemporal dementia, vascular 
dementia), Lewy body disease or mixed dementia) as 
determined by a clinician experienced in diagnosing 
dementia.7 Close in relationship refers to a CG who 
may be a sibling, spouse, adult child, friend, niece or 
nephew or any person who has a close relationship 
to the PwD, that is, anyone who is not a formal paid 
caregiver.
 ► Dyads where the PwD has a Neuropsychiatric 
Inventory- Questionnaire (NPI- Q) score of ≥6 (from a 
maximum score of 36) and Mini Mental State Exam-
ination (MMSE) scores <24 as research indicates that 
NPI- Q scores >6 occur in PwD who have high MMSE 
scores.23 The NPI- Q will form part of the screening 
process, with a trained assessor administering the 
NPI- Q in the dyad’s home prior to enrolment in the 
study.
Exclusion criteria:
 ► Dyads where either or both the CG or PwD have 
significant hearing impairments that are not resolved 
through the use of a hearing aid device and limit their 
capacity to enjoy musical experiences. There will be 
no further exclusions.
Interventions
Music intervention
Dyads randomly allocated to the MI will receive a 2- hour 
home- based MI training session that aims to engage 
the PwD during and following the MI. Using a carefully 
prepared and detailed intervention manual, a qualified 
music therapist will instruct the CG on methods and strat-
egies for using music to assist the PwD to become calmer 
(if agitated) or more energised (if apathetic). CGs will be 
instructed on how to choose music and engage the PwD 
in effective and respectful discussions with the aim of 
evoking autobiographical memories and sharing mean-
ingful experiences.24 Strategies to engage the PwD and 
create opportunities for meaningful dialogue with the 
PwD will be provided, as well as training CGs to notice the 
PwD’s positive and negative responses to music. The activ-
ities to be taught comprise: a) singing familiar/preferred 
songs followed by CG- facilitated discussions about the 
meaning of the songs for the dyad, the PwD and significant 
others, and any associated memories20 25; b) movement to 
music (eg, upper body and arms imitating familiar dance 
movements to music) to assist in regulating arousal11; 
c) playing instruments (or using household items to 
make rhythmic sounds) while listening to music and d) 
listening to familiar/preferred relaxing or enlivening 
music dependent on BPSD present at the time to assist 
in regulating arousal.20 CGs are then instructed to deliver 
the MI at least 5x per week for approximately 30 min over 
a 12- week period. After each MI session, they will diarise 
their experiences, including documenting which activities 
were used, session time and duration and any positive or 
negative responses during and after the session. Such data 
(number of times per week, average duration, activities 
adopted) will be used to monitor and improve adherence 
to the protocol. At 3 and 6 weeks post allocation, the MI 
trainer (music therapist) will return to the dyad’s home 
for a second and third training session (figure 2). These 
sessions aim to further extend CG knowledge and skills, 
troubleshoot any issues and improve protocol adherence. 
Fortnightly phone conversations with CGs will be used to 
support the CG and remind them to complete the diaries 
(to mitigate risk of non- completion and maximise partic-
ipant engagement, retention and protocol adherence).
Reading intervention (active control)
Dyads randomly allocated to the RI group will receive a 
2- hour RI instruction session which aims to engage the 
PwD during and following the RI. The reading activi-
ties will be taught by a qualified practitioner, following 
a carefully prepared and detailed intervention manual. 
These activities are based on RI methods commonly used 
with PwD including: a) CG reading aloud to the PwD; b) 
PwD reading aloud (or reciting poems, prayers, prose, 
short stories, fairy tales, when unable to read) to CG; c) 
listening to audio books and d) discussion of the text and 
personal responses.17–19 Strategies to engage the PwD 
and create opportunities for meaningful dialogue with 
the PwD will be provided as well as guidance on selecting 
reading material accessible to the PwD’s level of cogni-
tive impairment. CGs are then instructed to deliver RI at 
least 5x per week for 30 min over 12 weeks and diarise 
their reading activities to record activity and adherence. 
Diaries will serve as a mechanism to monitor adherence 
to the protocol. At 3 and 6 weeks post allocation, as per 
the MI condition, the RI trainers will return to the dyad’s 
home for a second and third training session with the 
intention of further extending CG knowledge and skills 
and to monitor and improve intervention protocol adher-
ence. Fortnightly phone conversations with CGs will be 
used to support the CG and remind them to complete the 
diaries (to mitigate risk of non- completion). Like the MI 
condition, phone calls also aim to maximise participant 
engagement, retention and protocol adherence.
For both the MI and RI, at screening, the assessors 
will determine the music and reading resources already 
available to the dyads. Should they require resources (eg, 
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large print books, mp3 players/speakers, downloadable 
music), the research team will loan these resources for 
the dyads, free of charge.
Standard care
For dyads randomly allocated to the SC condition, the CG 
will not be trained in either MI or RI but will be instructed 
to care for the PwD in their usual manner. This consists of 
providing medical, therapeutic and personal care, as well 
as participating in usual leisure activities.
Discontinuing or modifying Interventions
Where there is a significant deterioration in the health of 
the PwD and/or the CG that leads to hospital admission or 
care home admission, the MI or RI will be discontinued. 
If there is a change in primary CG partway through the 
study, the dyad will be withdrawn from the study.
Training and assessment of fidelity
Given the MI and RI will be delivered in five different 
countries with different healthcare philosophies and 
practices, a careful plan for fidelity of the study design, 
treatment integrity, treatment differentiation, treatment 
receipt and treatment enactment has been developed. 
A standardised manual for MI and RI has been devel-
oped and agreed on by all countries prior to implemen-
tation. Fidelity in this study is complex as it will involve 
assessing fidelity of the MI and RI training session, and 
fidelity of the CG- directed programme. Delivery of MI 
and RI training by research staff will be video- recorded 
and a randomised selection of 20% of recordings from 
every site will be reviewed by members of the research 
team and cross- checked with the MI and RI protocol 
manuals using a custom fidelity checklist. Individualised 
supervision and monitoring of intervention trainers will 
be employed to minimise ‘drift’ in trainer differences and 
control for differences in trainer styles. CG diaries will be 
used to determine whether the MI and RI protocols have 
been adhered to and the success of treatment enactment.
outcomes
At baseline, demographic data (age, gender and dyad 
history) of both CG and PwD will be collected as well as 
diagnostic information of PwD (ICD-10).
Where possible, core outcomes ( www. comet- initiative. 
org) for psychosocial intervention research in dementia 
care were selected.26 For the PwD, the following measures 
were selected:
 ► BPSD: the NPI- Q is the most highly regarded and 
used measure for determining the severity of BPSD 
in clinical trials. The 12- item scale is used to assess the 
behaviour of PwD across 12 domains of commonly 
displayed BPSD. The scale has been translated into >40 
languages, has been cross- validated against the NPI 
as the gold standard (r=0.73) and has demonstrated 
good validity (sensitivity=74.1%, specificity=79.5%), 
internal reliability (α=0.783) and excellent test–retest 
reliability (r=0.99).27 28 Total severity scores range 
from 0 to 36; higher values are indicative of higher 
severity. Distress scores range from 0 to 60; higher 
values represent higher levels of distress. CGs will self- 
complete the NPI- Q with guidance from the research 
assessor if required.
 ► Depression: the Montgomery Asberg Depression 
Rating Scale (MADRS)29 will be used to assess the 
severity of depression. Scores for each of the 10 items 
range from 0 (no symptoms) to 6 (severe symptoms) 
and are determined through an assessor- led inter-
view with the proxy, in this study, the CG. Total score 
ranges from 0 to 60 with higher scores indicating 
more severe depression. The MADRS has been found 
to have good constructive validity, internal reliability 
(α=0.84) and test–retest reliability (intraclass correla-
tion coefficient=0.78). The scale has been widely used 
in clinical trials.29
 ► QoL: the QoL of PwD will be determined by admin-
istering the QoL- AD30 scale. The QoL- AD is recom-
mended by the COMET Initiatve,26 for use in clinical 
effectiveness trials. It is a simple 13- item self- report 
measure, which is rated on a 4- point scale, within 
the structure of a verbally delivered interview. Total 
scores range from 13 (poor QoL) to 52 (excellent 
QoL in all areas). Studies indicate that the measure 
can demonstrate sensitivity to psychosocial interven-
tion, correlates with health- utility measures,31 has 
excellent inter- rater reliability (κ>0.70) and internal 
consistency (α=0.82). The QoL- AD is reliable when 
used with people with MMSE scores of >10. Both a 
CG proxy and PwD self- report (if possible) will be 
collected at the three time points. If the PwD is able 
to complete the MMSE at all time points, then their 
response will be included in the analysis. If not, then 
the proxy version at all time points will be used.
 ► Cognition: the MMSE will be administered preinter-
vention and postintervention (time 1 and time 2) to 
monitor any change in the PwD’s cognition and to 
examine the relationship between cognitive decline, 
BPSD, depression and response to different condi-
tions. The MMSE is a 30- point questionnaire used 
to estimate the severity and progression of cognitive 
impairment and to follow the course of cognitive 
changes in an individual over time.32 The MMSE tests 
for orientation, attention, memory, language and 
visual- spatial skills. It is reliable and valid for both 
diagnosis and longitudinal assessment. Higher scores 
indicate better cognitive capacity with scores of 24–30 
indicating no cognitive impairment; 19–23 indi-
cating mild cognitive impairment; 10–18 indicating 
moderate cognitive impairment and scores <10 indi-
cating severe cognitive impairment. MMSE scores will 
be determined through assessor- led interviews with 
PwD participants.
For the CG, the following measures were selected:
 ► Depression: CG depression will be measured using 
the Patient Health Questionnaire-9 (PHQ-9).33 This 
self- completed 9- item questionnaire asks the partici-
pant about how often they experience the descriptors 
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over the last 2 weeks. Each item is scored from 0 (not 
at all) to 3 (nearly every day). Total scores range from 
0 to 27. The PHQ-9 has comparable sensitivity and 
specificity to other depression measures; high internal 
reliability (α=0.89) and test–retest reliability (r=0.84).
 ► Resilience: CG resilience will be measured using the 
self- completed 14- item Resilience Scale.34 Total scores 
range from 14 to 98, with higher scores indicative of 
higher resilience. The measure has been tested and 
has good concurrent validity, good internal reliability 
(α=0.8–0.90), good construct validity, test–retest reli-
ability (r=0.67–0.84) and has been translated into 36 
languages.35
 ► Competence: CG competence will be measured using 
the self- completed Short Sense of Competence Ques-
tionnaire.36 The 7- items cover three main domains: 
self- reported feelings about how the caregiver role 
impacts the CG’s personal life, satisfaction with their 
performance as a CG and their satisfaction with how 
the PwD responds to the CG. Total scores ranged from 
7 to 35 with higher scores indicative of a stronger 
sense of competence. The measure has been cross- 
validated with the longer 35- item standard Sense of 
Competence Questionnaire (r=0.88) and has been 
shown to have high reliability (Cronbach’s α=0.76).
 ► QoL: CG QoL will be assessed using the self- completed 
Assessment of Quality of Life- 6D instrument.37 Each 
item asks participants to describe their situation over 
the past week by ticking the box (from 4 to 6 choices) 
that best reflects their situation. The psychometric 
property testing found the instrument to be reliable 
and valid, and has greater sensitivity to the psycho-
social dimensions of QoL than other utility instru-
ments.37 38
 ► Relationship quality: CG perception of quality of the 
CG and PwD relationship will be captured by asking 
the CG to self- complete the Quality of Caregiver- 
Patient Relationship.39 This 14- item measure aims 
to capture the strength of the quality of relationship 
between the PwD and CG, from the CG’s perspective. 
Total scores range from 14 to 70, with higher scores 
indicating a higher quality relationship. The measure 
has demonstrated acceptable internal consistency 
(α=0.82) and concurrent validity.
 ► Adherence to the MI/RI intervention will be meas-
ured through CG completed diaries. CGs are deemed 
adherent to the protocol if they have provided >2 
sessions of MI or RI per week, for at least 30 min in 
total. Data on the general use of reading and music by 
all dyads (including SC) will be collected at post- test. 
For each diary entry, CGs will be asked to record the 
date, start and stop time of MI/RI engagement, types 
of activities used, their experiences during the session 
(negative, neutral, positive, unsure), effects from 
the intervention for the remainder of the day until 
the PwD goes to bed for the evening sleep (negative, 
neutral, positive, unsure) and any comments. These 
data will be used in qualitative analyses to gain more 
nuanced understandings of how the activities are 
perceived and how these may change over the course 
of the intervention period.
To evaluate the cost- effectiveness of MI compared with 
RI and SC on PwD and CG, the following outcomes will 
be measured:
 ► Quality- adjusted life- years (QALYs): the EuroQol 
instrument (EQ- 5D- 5L),40 is a generic QoL measure 
that is internationally used to determine the QALYs 
and used for clinical and economic appraisal.40 
The measure is quick to complete and not cogni-
tively demanding. Scores from the five items are 
not combined arithmetically but using preference 
weights which arrive at an overall QoL score. These 
range from lower than 0 (worse than death) to 1 (best 
possible). PwD will complete the self- report version 
of the EQ- 5D- 5L. CGs will complete the measure as 
a proxy for the PwD and self- report their own health 
status.26 41–44
 ► Resource utilisation in dementia (RUD): the RUD 
is a standardised instrument for resource use data 
collection in dementia, designed to collect data from 
formal and informal care across different countries. 
The RUD assesses resource use of both PwD and CG, 
including time expended in different daily tasks, and 
consists of baseline and a follow- up assessment.45 The 
RUD will be completed through assessor- led inter-
views with CGs.
CGs will be provided with a set of guidelines as to how 
to complete the diary and all self- report and proxy meas-
ures. The schedule for enrolment, baseline assessments, 
all outcome measures, and intervention trainings is 
outlined in figure 3.
Sample size
A total of 165 dyads in each arm of the study, or 495 in 
total, are needed to detect a difference of 3- points in 
NPI- Q total severity score (primary outcome) between 
the MI plus SC and SC arm (primary comparison) at 12 
weeks (primary time point). This assumes 90% power, a 
two- tailed significance level of 5%, equal SD (7.5 points) 
in the groups, no correlation between baseline and 12 
weeks (conservative) and 20% attrition. A 3- point change 
from baseline in NPI- Q total severity score is considered 
a clinically meaningful difference.46 A conservative SD of 
7.5 points is based on that observed in 1026 community- 
living participants across eight European countries with 
mild- to- severe dementia (SD 5.9–6.5 points).47 48 A conser-
vative drop- out proportion (eg, withdrawn by CG, physi-
cian or death) of 20% is based on a reported 5.6% (95% 
CI 1.8% to 12.6%) drop- out at 3 months in 89 inpatients 
with mild- to- moderate dementia in Finland participating 
in a three- arm RCT of singing, music or usual care,.25
recruitment
Randomisation will aim to be distributed equally across 
five countries (Australia, the UK, Norway, Germany and 
Poland) to support between- country analyses. Participants 
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Figure 3 Schedule of enrolment, interventions and assessments. AQoL- 6D, assessment of quality of life- 6D instrument; EQ- 
5D- 5L, the EuroQol instrument; ICD-10, 10th revision of the International Statistical Classification of Diseases and Related 
Health Problems; MADRS, Montgomery Asberg Depression Rating Scale; MI, music intervention; MMSE, Mini Mental State 
Examination Score; NPI- Q, Neuropsychiatric Inventory; PHQ-9, Patient Health Questionnaire-9; QALY, quality- adjusted life- 
years; QCPR, quality of caregiver- patient relationship; QoL- AD, quality of life- Alzheimer’s disease; RI, reading intervention; RS, 
Resilience Scale; RUD, resource utilisation in dementia; SSCQ, Short Sense of Competence Questionnaire.
will be recruited through established partner organisa-
tions. Staff from the partner organisations will introduce 
the trial to potential participants and invite them to partic-
ipate in the study. They will be given an information sheet 
explaining the main aspects of the trial and provided with 
contact details of the research team who will be available 
to answer further questions.
randomisation, allocation concealment and blinding
The randomisation schedule will be computer- generated 
by an independent statistician and allocation will be carried 
out through a centralised randomisation service. Block 
permuted randomisation with stratification by partici-
pating site will be used, so that treatment balance within 
site is achieved. Dyads who meet the inclusion criteria and 
none of the exclusion criteria will be randomised 1:1:1 
into MI, RI or SC. Randomisation will occur after the 
eligibility checking, informed consent and baseline assess-
ment have been completed. Informed consent/assent will 
be obtained by a blinded assessor prior to the baseline 
assessment. The study coordinator in each country will be 
informed of the allocation and will inform dyads of their 
group allocation by post, phone or email.
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Participant dyads cannot be fully blinded due to 
the active nature of the interventions; however, plain 
language statements and consent forms will use neutral 
wording to maintain equipoise and to avoid expectancy 
effects. Blinded assessors will collect participants’ data at 
baseline, postintervention and follow- up. Diaries will be 
returned in sealed envelopes to minimise risk of assessors 
becoming unblinded. The success of assessor blinding will 
be checked by asking the assessor to guess the treatment 
assignment (or say “I do not know”) after the postinter-
vention and follow- up periods. This treatment guess will 
then be compared against the actual treatment and the 
blinding index derived. The independent statistician 
will not reveal the allocation codes to any of the study 
team except for the study coordinators of each country in 
charge of group allocation. All other investigators and the 
study statistician will remain blinded until the database 
has been cleaned, a blinded data review has taken place 
and the database is ready for analysis.
Analysis
Analyses will be performed on an intention- to- treat basis 
including all randomised dyads in their allocated study 
arm. The primary outcome (NPI- Q severity total score) 
will be analysed using a constrained longitudinal data 
analysis (cLDA) model,49 with response consisting of all 
scores (baseline, 12 weeks and 6 months) and the model 
including factors representing intervention, time, inter-
vention by time interaction and site with the restriction 
of a common baseline mean score across interventions. 
This refers to the assumption that at baseline there are 
no differences between the interventions in the mean 
score, thus assuming the randomisation was effective. 
This assumption will be enforced statistically in the statis-
tical model. The absolute difference between MI and SC 
and MI and RI in mean change from baseline will be esti-
mated (including two- sided 95% CI) at 12 weeks (primary 
time point). A hierarchical fixed sequence testing proce-
dure will allow testing of MI versus RI at 12 weeks at 5% 
if the comparison of MI versus SC at 12 weeks has a p 
value <0.05. Secondary analyses will consist of a model 
adjusted for potential confounders (types of dementia 
and gender). The cLDA model provides valid infer-
ence if the missing data mechanism is at most missing at 
random. In addition to the intention- to- treat effect, we 
will obtain the complier average causal effect by making 
use of the collected adherence data.50 Analyses similar 
to the primary outcome will be applied to the secondary 
outcomes for PwD and CGs. Heterogeneity of the inter-
vention effect across subgroups (gender of the PwD/CG, 
types of dementia, severity of dementia, time of onset 
dementia, length of time having dementia, relationship 
between PwD and CG, country) will be assessed by means 
of interaction tests. The number and percentage of PwDs 
and CGs with adverse events will be summarised by inter-
vention group.
Cost- effectiveness analysis in a societal perspective 
will be performed separately for each country using the 
utilities generated by EQ- 5D- 5L for both PwD and CG and 
country- specific weights, to estimate a combined QALY 
score using a generalised linear model adjusted by the 
baseline. Health and informal care resources consumed 
by PwD will be assessed using the RUD and unit cost by 
country. A generalised linear mixed model will be used 
to estimate the main predictors of the total costs in the 
MI, RI and SC groups. Incremental cost- effectiveness 
ratio will be calculated using the cost and effect estimates 
comparing MI with RI and SC. The uncertainty around 
the incremental cost- effectiveness ratio will be estimated 
using bootstrapping (1000 replications) adjusting to 
control variables.
Patient and public involvement
All countries have involved user and advocacy organisa-
tions in the development and design of the study. The 
UK, Australia and Germany have been piloting work with 
formal and informal CGs of PwD for many years. CGs 
and PwD have been involved designing the diaries which 
capture adherence data. It was imperative that the diary 
be user- friendly, not burdensome on the CG, and yet 
enabled them to document both the positive and nega-
tive aspects of the session. Several iterations of the diary 
were constructed prior to arriving at the final structure. 
Pilot work in Australia14 involved interviews postinter-
vention to identify strengths, limitations, challenges and 
experiences in delivering the MI, as well as recommen-
dations for suggested modifications to the intervention 
training. Representatives of advocacy groups and end 
users from all countries will be represented on an inter-
national Participant and Public Involvement Committee.
Monitoring and oversight
A Trial Operations Committee (TOC) will comprise the 
principal investigator, chief investigators and clinical trial 
managers from each of the five countries, the study stat-
istician, health economist and a consumer representa-
tive. The TOC will meet at least 6- weekly, and will oversee 
all aspects of the trial delivery including strategies to 
support efficient and effective recruitment and retention, 
reviewing completeness of data sets, monitoring interven-
tion fidelity, management of timelines and milestones, 
review of country- by- country progress, public and patient 
involvement or actions and publication and dissemina-
tion plans. The role of the members of the TOC is to 
bring country- specific issues to the international team 
for discussion to ensure the study is being monitored and 
delivered according to the agreed protocols. Protocol 
deviations and any changes or amendments to the opera-
tional processes of the trial will be discussed and decisions 
made by the TOC.
A Trial Steering Committee will comprise members 
independent of the clinical trial including consumer 
representatives and representatives from other rele-
vant advocacy organisations. The trial principal inves-
tigator (or a proxy in her absence) will also sit on the 
committee as a non- voting member. The Committee will 
Protected by copyright.
 o
n
 D
ecem
ber 2, 2019 at Anglia Ruskin University - Library.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-031332 on 19 November 2019. Downloaded from 
9Baker FA, et al. BMJ Open 2019;9:e031332. doi:10.1136/bmjopen-2019-031332
Open access
meet biannually (or more often when needed) to review 
and monitor all aspects of the study delivery. They will 
draw on reports provided to them by the TOC and make 
recommendations to the principal investigator and TOC 
about whether further actions are required.
A Data Safety Management Committee (DSMC) will 
review the cumulative study data to evaluate the recruit-
ment, safety, study conduct and scientific validity and 
integrity of the trial. The committee consists of at least 
five people with strong methodological, biostatistical and 
clinical expertise who are independent of the project and 
an end user representative. The DSMC will be provided 
with data on recruitment, intervention uptake, any 
unforeseen and/or adverse events and review serious 
adverse events. The meetings will consist of an open and a 
closed part. In the open part, the general progress of the 
trial will be discussed with the principal investigator. In 
the closed part, the DSMC will discuss any safety concerns 
and if considered required, the DSMC will make recom-
mendations to the TOC for appropriate action.
Study data will be collected and managed using REDCap 
electronic data capture tools hosted at the University 
of Melbourne.51 The Data Management Coordinating 
Center will oversee the intrastudy data sharing process 
between countries, with input from the Data Manage-
ment Subcommittee. We will develop a data management 
manual detailing data collection protocols and provide 
comprehensive training of those members of the research 
team who collect, check and enter study data. The prin-
cipal investigator, study statistician and health economist 
from the University of Melbourne will be given access to 
the cleaned data sets. Country- specific lead investigators 
will only have access to their own country’s cleaned data 
sets. All data sets will be password- protected. To ensure 
confidentiality, data dispersed to project team members 
will have any identifying information removed.
risk management
Processes have been put in place to mitigate risks. One 
of the most significant risks associated with the project is 
slow recruitment. To offset the risk of slow recruitment, 
data are being collected across five countries. If some 
countries have less difficulty than others in recruiting, 
then these countries will recruit greater numbers to 
ensure the required sample size is obtained. Another risk 
identified is the heterogeneity of intervention delivery. 
The inclusion of a detailed manual, regular supervision 
with interventionists, and monitoring the effectiveness 
of interventionist training will mitigate the risk of poor 
intervention fidelity.
Ethics and dissemination plan
All research and clinical activities carried out for the 
HOMESIDE project will be in compliance with funda-
mental ethical principles including those reflected in the 
Oviedo convention and the Convention for the Protection 
of Human Rights and Fundamental Freedoms and legal 
requirements (Directive 95/46/EC on the protection of 
individuals with regard to the processing of personal data 
and on the free movement of such data; and Directives 
2001/20/EC, 2005/28/EC relating to the implementa-
tion of good clinical practice in the conduct of clinical 
trials). Ethical conduct will be managed in the following 
ways:
 ► The clinical trial coordinator in each country will 
implement the research in full respect of European/
national/ institutional legal and ethical requirements 
and codes of practice.
 ► Ethics approvals in each country must be obtained 
prior to commencement of the trial.
 ► Informed consent from the PwD’s guardian must be 
obtained prior to enrolling a participant in the study. 
Assent from the PwD will always be sought prior to 
enrolment in the study.
 ► National and international rules on data protec-
tion will be followed. Participating countries in 
HOMESIDE within the EU and EEA (UK, Germany, 
Poland and Norway) also relate to the General Data 
Protection Regulation (GDPR)(Regulation (EU) 
2016/679), designed to harmonise data privacy laws 
across Europe, to protect and empower all EU citi-
zens data privacy and to reshape the way organisa-
tions across the region approach data privacy. The 
HOMESIDE partners have also signed a consortium 
agreement where they consent to follow national and 
international rules on collaboration, ethics and data 
protection.
The report on the main, preplanned analyses of the 
primary end point and up until the 6- month follow- up 
will be submitted to a leading medical journal. Further 
publications may focus on issues such as recruitment and 
retention strategies for home- based programmes. Publi-
cations based on qualitative interviews and video analyses 
will focus on barriers and facilitators for implementation 
and promotion of adherence to home- based programmes; 
experiences of caregivers in delivering the programmes 
and the development of best practice training guide-
lines. In addition to publications in academic journals, 
a number of policy briefing papers for government and 
aged care/dementia advocacy groups are planned as well 
as the development of training manuals and guidelines 
for dissemination.
data sharing
In accordance with the Australian Code for Responsible 
Conduct of Research (Universities Australia, 2018), all 
data will be retained for retrieval and reuse in future 
research where participant permission is granted. 
Following project completion, de- identified anony-
mised data (with participant consent) will be available 
on the Australian Data Archive https:// ada. edu. au and 
listed on Research Australia’s https:// researchaustralia. 
org website to facilitate access for future research. Data 
made available will include individual- level deidentified 
participant data, reports on adverse events and deiden-
tified interview transcripts. According to the GDPR, the 
Protected by copyright.
 o
n
 D
ecem
ber 2, 2019 at Anglia Ruskin University - Library.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-031332 on 19 November 2019. Downloaded from 
10 Baker FA, et al. BMJ Open 2019;9:e031332. doi:10.1136/bmjopen-2019-031332
Open access 
consortium have agreed to the reuse of data for 10 years 
post project completion.
relevance and benefit to society
As the majority of PwD live in the community and not 
in residential care settings, quality informal care for 
PwD is crucial for managing BPSD and enhancing QoL. 
This protocol details the process for testing the effec-
tiveness and cost- effectiveness of a CG- directed MI and 
RI designed to manage the BPSD of PwD, the sense of 
burden and well- being of the CG and provide meaningful 
possibilities to maintain the relationship between PwD 
and their CGs. We expect that with support and training, 
the MI will be easily implemented in the family home by 
CGs. With the increasing number of people living with 
dementia and the stress this will place on countries’ econ-
omies, our project aims to test an intervention designed to 
keep people living at home with family CGs for as long as 
possible, reducing the burden for society and caregivers. 
Our study will be able to estimate the incremental cost- 
effectiveness ratio between MI and RI, MI and SC and RI 
and SC. Data may support aged care policy recommen-
dations and as the interventions will be delivered in five 
different countries, results will be broadly generalisable.
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